Emami, Michael R.
Brimble, Mark A.
Espinoza, Alejandro
Owens, Jane
Whiteley, Laurence O.
Casinghino, Sandra
Lanz, Thomas A.
Farahat, Philip K.
Pellegrini, Matteo
Young, Courtney S.
Thomas, Paul G.
McNally, Elizabeth M.
Villalta, S. Armando
Schattgen, Stefan A.
Spencer, Melissa J. https://orcid.org/0000-0001-7104-544X
Funding for this research was provided by:
American Lebanese Syrian Associated Charities
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01NS047726)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01HL061322)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (P50AR052646)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01NS120060)
National Institute of Allergy and Infectious Diseases (R01AI136514)
National Institute of Allergy and Infectious Diseases (R21AI169085)
National Institute of Allergy and Infectious Diseases (U01AI150747)
Cystic Fibrosis Foundation Therapeutics Inc
Pfizer
US Department of Defense
National Institute of Neurological Disorders and Stroke (R01NS117912)
Petroleum Technology Alliance Canada
Cystic Fibrosis Foundation
National Institutes of Health
This article is maintained by: Elsevier
Article Title: Single cell and TCR analysis of immune cells from AAV gene therapy-dosed Duchenne muscular dystrophy patients
Journal Title: Molecular Therapy - Methods & Clinical Development
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.omtm.2024.101349
Content Type: article
Copyright: © 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.